glp-1 receptor agonist agonists for individualized treatment of type 2 diabetes mellitus GLP-1 Receptor Agonists Show Promise

doi:10.1007/s12017-012-8184-z 136

Loss of bone density in patients with anorexia nervosa food that alone will not cure

In contrast, the pharmacological nanomolar concentrations of GLP-1RAs predominantly activate the cAMP/PKA pathway, potentially explaining their broader therapeutic effects [122]

Indeed, eGFR values were greater in patients on tirzepatide compared to those on insulin glargine, with a mean eGFR decline rate of 1.4 ml/min/1.73 m 2 per year in tirzepatide users and a between-group difference in eGFR reduction of 2.2 ml/min/1.73 m 2 per year [49]

Further clarification on the hepatic benefits of GLP-1RA is urgently needed, as these insights could contribute to explaining the pharmacological actions in MASLD and the formulation of clinical strategies

J Mol Biol 432: 1347-1366, 2020